Nektar Therapeutics (LTS:0UNL)
$ 1.0304 -0.0065 (-0.63%) Market Cap: 188.15 Mil Enterprise Value: 51.91 Mil PE Ratio: 0 PB Ratio: 3.86 GF Score: 53/100

Nektar Therapeutics at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 11, 2021 / 07:50PM GMT
Release Date Price: $18.1
Jessica Macomber Fye
JPMorgan Chase & Co, Research Division - Analyst

Great. Good afternoon, everyone. My name is Jess Fye. I'm one of the senior biotech analysts at JPMorgan. And we're continuing the health care conference today with Nektar Therapeutics. I'm joined by the company's CEO, Howard Robin.

And unlike typically at the conference where we would go across the hall for question and answers, this session is going to move seamlessly into a Q&A session once Howard is done with the presentation. And if you use the blue ask-the-question button online, you can send questions to me via the portal, and I can ask them to management in our virtual breakout session.

So with that, let me pass it over to Howard.

Howard W. Robin
Nektar Therapeutics - CEO, President & Director

Okay. Thank you, Jessica, for inviting us to speak again at the JPMorgan Healthcare Conference and kick off the New Year.

Before I get started, I will show you a slide on forward-looking statements. So please go to the next slide. And I'm going to be

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot